Investment
Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
MarketWatch
The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.
Read the full story at the original publisher
MarketWatch →
-
These surprising stocks could be some of the biggest drivers of S&P 500 earnings growthMarketWatch16 hours ago
Leave a Reply